Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
12.57
+0.01 (0.08%)
At close: Aug 1, 2025, 4:00 PM
12.33
-0.24 (-1.91%)
After-hours: Aug 1, 2025, 4:08 PM EDT
Zymeworks Employees
As of December 31, 2024, Zymeworks had 286 total employees, including 280 full-time and 6 part-time employees. The number of employees increased by 8 or 2.88% compared to the previous year.
Employees
286
Change (1Y)
8
Growth (1Y)
2.88%
Revenue / Employee
$326,517
Profits / Employee
-$397,476
Market Cap
940.80M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 286 | 8 | 2.88% |
| Dec 31, 2023 | 278 | -16 | -5.44% |
| Dec 31, 2022 | 294 | -164 | -35.81% |
| Dec 31, 2021 | 458 | 103 | 29.01% |
| Dec 31, 2020 | 355 | 99 | 38.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ZYME News
- 5 days ago - Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate - GlobeNewsWire
- 16 days ago - Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - GlobeNewsWire
- 7 weeks ago - Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade) - Seeking Alpha
- 2 months ago - Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - GlobeNewsWire
- 2 months ago - Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - GlobeNewsWire
- 2 months ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference - GlobeNewsWire
- 3 months ago - Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript - Seeking Alpha